See the latest news and media coverage for Oxcia. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company developing oxidative DNA damage response therapeutics
oxcia.comLast updated
In short: Oxcia secured Orphan Drug Designations for its IPF treatment OXC-201 and announced plans to raise approximately 90 million SEK.
The meeting will address the issuance of convertible bonds and authorization for new share issues directed towards Thomas Helleday and Smärtafonden ahead of the planned listing.
She brings over a decade of respiratory disease expertise and will lead preclinical development of OXC-201.
The annual report is available on the website and the CEO comments on the first collaboration agreement as well as ODD from two supervisory authorities.
The meeting will consider authorization for issuance of shares, warrants, and convertibles.
Article ‘Count’ and ‘Share’ for Oxcia AB based on listed parameters only. According to the parameters selected above, there are no articles from Oxcia AB...
Track Oxcia and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.